Liquidia

Liquidia Debt

The Debt of Liquidia (LQDA) as of Nov 17, 2026 is 197.93 M USD. In the previous year, Debt was 122.39 M USD — a change of 61.72% (higher).

Debt

197.93 MUSD

YoY

61.72%

Last updated:

In 2025, Liquidia's total debt was 197.93 M USD, a 61.72% change from the 122.39 M USD total debt recorded in the previous year.

The Liquidia Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
12.77 M USD
Jan 1, 2019
24.42 M USD
Jan 1, 2020
17.14 M USD
Jan 1, 2021
16.08 M USD
Jan 1, 2022
24.46 M USD
Jan 1, 2023
49.54 M USD
Jan 1, 2024
122.39 M USD
Jan 1, 2025
197.93 M USD
The Liquidia Debt history
YEARDebtYoY
197.93 MUSD+61.72%
122.39 MUSD+147.07%
49.54 MUSD+102.49%
24.46 MUSD+52.13%
16.08 MUSD-6.20%
17.14 MUSD-29.79%
24.42 MUSD+91.15%
12.77 MUSD-45.62%
23.49 MUSD+170.54%
8.68 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Liquidia Stock analysis

What does Liquidia do? Liquidia Corp is a biopharmaceutical company specializing in the development of novel therapeutic products using an advanced technology called Liqutex. This technology allows for precise control over the size, shape, and surface properties of particles, enabling targeted release of active ingredients in the body. The company was founded in 2004 as a spin-off from the University of North Carolina at Chapel Hill. It has been supported by prominent investors such as PPD, Inc. and New Enterprise Associates to advance the development of new drugs. Liquidia's business model is based on creating a comprehensive product portfolio with applications in various therapeutic areas, including immunology, oncology, infectious diseases, and pulmonary hypertension. The idea is to cover a wide range of applications with the Liqutex technology to increase competitiveness in the market. To achieve this, Liquidia has formed partnerships with other companies and research institutions to advance therapeutic development. For example, it collaborates with GlaxoSmithKline on the development of vaccines for pertussis and influenza. Another important aspect of Liquidia's business model is the creation of differentiated products that address a broader range of patient needs. For instance, the company has developed a novel drug combination for the treatment of pulmonary hypertension, which exhibits better efficacy and tolerability due to its specific formulation. In addition to its focus on therapeutic applications, Liquidia has also developed a range of products for industrial use. For example, it has a specialized technology for producing high-quality nanoparticles for the electronics industry. Overall, Liquidia stands out for its versatility and innovative solutions. The company has a unique technology platform that allows it to create differentiated products for both the medical and industrial sectors. Supported by an experienced management team and prominent investors, Liquidia is pursuing a holistic growth strategy to maintain a leading role in the biotechnology industry. Liquidia Corp is a biopharmaceutical company specializing in the development of novel therapeutic products using an advanced technology called Liqutex. The company was founded in 2004 as a spin-off from the University of North Carolina at Chapel Hill and has received support from investors such as PPD, Inc. and New Enterprise Associates. Liquidia's business model focuses on creating a comprehensive product portfolio with applications in various therapeutic areas, including immunology, oncology, infectious diseases, and pulmonary hypertension. The company aims to cover a wide range of applications with its Liqutex technology to increase competitiveness in the market. To achieve this, Liquidia has formed partnerships with other companies and research institutions, such as GlaxoSmithKline, to advance therapeutic development. Additionally, Liquidia prioritizes the creation of differentiated products that address a broader range of patient needs, such as a novel drug combination for the treatment of pulmonary hypertension. In addition to therapeutic applications, Liquidia has also developed products for industrial use, such as specialized technology for producing nanoparticles for the electronics industry. Liquidia distinguishes itself through its versatility and innovative solutions, with a unique technology platform and a holistic growth strategy supported by an experienced management team and prominent investors. Liquidia is one of the most popular companies on Eulerpool.

Debt Details

Understanding Liquidia's Debt Structure

Liquidia's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Liquidia's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Liquidia’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Liquidia’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Liquidia stock

Debt of Liquidia is 197.93 M USD in 2025.

Debt of Liquidia changed from 122.39 M USD to 197.93 M USD, representing a 61.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Liquidia since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Liquidia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Liquidia

All Key Metrics — Liquidia